Toru Takiguchi1, Mikio Nakajima2,3, Hiroyuki Ohbe2, Yusuke Sasabuchi4, Hiroki Matsui2, Kiyohide Fushimi5, Shiei Kim1, Hiroyuki Yokota1, Hideo Yasunaga2. 1. Department of Emergency and Critical Care Medicine, Nippon Medical School, Tokyo, Japan. 2. Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. 3. Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan. 4. Data Science Center, Jichi Medical University, Tochigi, Japan. 5. Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.
Abstract
OBJECTIVES: Previous studies have suggested that vasodilator therapy may be beneficial for patients with nonocclusive mesenteric ischemia. However, robust evidence supporting this contention is lacking. We examined the hypothesis that vasodilator therapy may be effective in patients diagnosed with nonocclusive mesenteric ischemia. DESIGN: Retrospective cohort study. SETTING: The Japanese Diagnosis Procedure Combination inpatient database. PATIENTS: A total of 1,837 patients with nonocclusive mesenteric ischemia from July 2010 to March 2018. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We compared patients who received vasodilator therapy (vasodilator group; n = 161) and those who did not (control group; n = 1,676) using one-to-four propensity score matching. Vasodilator therapy was defined as papaverine and/or prostaglandin E1 administered via venous and/or arterial routes within 2 days of admission. Only patients who did not receive abdominal surgery within 2 days of admission were analyzed. The main outcomes were in-hospital mortality and abdominal surgery performed greater than or equal to 3 days after admission. After propensity score matching, in-hospital mortality was significantly lower in the vasodilator group (risk difference, -11.6%; p = 0.005). The proportion of patients who received abdominal surgery at greater than or equal to 3 days after admission was also significantly lower in the vasodilator group (risk difference, -10.2%; p = 0.002). CONCLUSIONS: Vasodilator therapy with papaverine and/or prostaglandin E1 is associated with lower in-hospital mortality and prevalence of abdominal surgery in patients with nonocclusive mesenteric ischemia.
OBJECTIVES: Previous studies have suggested that vasodilator therapy may be beneficial for patients with nonocclusive mesenteric ischemia. However, robust evidence supporting this contention is lacking. We examined the hypothesis that vasodilator therapy may be effective in patients diagnosed with nonocclusive mesenteric ischemia. DESIGN: Retrospective cohort study. SETTING: The Japanese Diagnosis Procedure Combination inpatient database. PATIENTS: A total of 1,837 patients with nonocclusive mesenteric ischemia from July 2010 to March 2018. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We compared patients who received vasodilator therapy (vasodilator group; n = 161) and those who did not (control group; n = 1,676) using one-to-four propensity score matching. Vasodilator therapy was defined as papaverine and/or prostaglandin E1 administered via venous and/or arterial routes within 2 days of admission. Only patients who did not receive abdominal surgery within 2 days of admission were analyzed. The main outcomes were in-hospital mortality and abdominal surgery performed greater than or equal to 3 days after admission. After propensity score matching, in-hospital mortality was significantly lower in the vasodilator group (risk difference, -11.6%; p = 0.005). The proportion of patients who received abdominal surgery at greater than or equal to 3 days after admission was also significantly lower in the vasodilator group (risk difference, -10.2%; p = 0.002). CONCLUSIONS: Vasodilator therapy with papaverine and/or prostaglandin E1 is associated with lower in-hospital mortality and prevalence of abdominal surgery in patients with nonocclusive mesenteric ischemia.
Authors: Miklosh Bala; Fausto Catena; Jeffry Kashuk; Belinda De Simone; Carlos Augusto Gomes; Dieter Weber; Massimo Sartelli; Federico Coccolini; Yoram Kluger; Fikri M Abu-Zidan; Edoardo Picetti; Luca Ansaloni; Goran Augustin; Walter L Biffl; Marco Ceresoli; Osvaldo Chiara; Massimo Chiarugi; Raul Coimbra; Yunfeng Cui; Dimitris Damaskos; Salomone Di Saverio; Joseph M Galante; Vladimir Khokha; Andrew W Kirkpatrick; Kenji Inaba; Ari Leppäniemi; Andrey Litvin; Andrew B Peitzman; Vishal G Shelat; Michael Sugrue; Matti Tolonen; Sandro Rizoli; Ibrahima Sall; Solomon G Beka; Isidoro Di Carlo; Richard Ten Broek; Chirika Mircea; Giovanni Tebala; Michele Pisano; Harry van Goor; Ronald V Maier; Hans Jeekel; Ian Civil; Andreas Hecker; Edward Tan; Kjetil Soreide; Matthew J Lee; Imtiaz Wani; Luigi Bonavina; Mark A Malangoni; Kaoru Koike; George C Velmahos; Gustavo P Fraga; Andreas Fette; Nicola de'Angelis; Zsolt J Balogh; Thomas M Scalea; Gabriele Sganga; Michael D Kelly; Jim Khan; Philip F Stahel; Ernest E Moore Journal: World J Emerg Surg Date: 2022-10-19 Impact factor: 8.165